EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response

Rebekah Crake, Imène Gasmi, Jordan Dehaye, Fanny Lardinois, Raphaël Peiffer iD, Naïma Maloujahmoum, Ferman Agirman, Benjamin Koopmansch iD, Nicky D'Haene, Oier Azurmendi Senar, Tatjana Arsenijevic, Frédéric Lambert iD und 3 weitere

Cells · 17.05.2023 · 12 (10) · 1414

DOI: 10.3390/cells12101414 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 17.05.2023. Verfasst von Rebekah Crake und 14 weiteren Autor:innen. Beteiligte Einrichtung: Metastasis Research Laboratory, GIGA-Cancer, GIGA Institute, University of Liège, 4020 Liège, Belgium. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: collaborative FNRS grant awarded to A.B. and J.-L.V.L., University of Liège, “Fondation Léon Fredericq”.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with poor prognosis. Gemcitabine is the first-line therapy for PDAC, but gemcitabine resistance is a major impediment to achieving satisfactory clinical outcomes. This study investigated whether methylglyoxal (MG), an oncometabolite spontaneously formed as a by-product of glycolysis, notably favors PDAC resistance to gemcitabine. We observed that human PDAC tumors expressing elevated levels of glycolytic enzymes together with high levels of glyoxalase 1 (GLO1), the major MG-detoxifying enzyme, present with a poor prognosis. Next, we showed that glycolysis and subsequent MG stress are triggered in PDAC cells rendered resistant to gemcitabine when compared with parental cells. In fact, acquired resistance, following short and long-term gemcitabine challenges, correlated with the upregulation of GLUT1, LDHA, GLO1, and the accumulation of MG protein adducts. We showed that MG-mediated activation of heat shock response is, at least in part, the molecular mechanism underlying survival in gemcitabine-treated PDAC cells. This novel adverse effect of gemcitabine, i.e., induction of MG stress and HSR activation, is efficiently reversed using potent MG scavengers such as metformin and aminoguanidine. We propose that the MG blockade could be exploited to resensitize resistant PDAC tumors and to improve patient outcomes using gemcitabine therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansGemcitabinePyruvaldehydeDeoxycytidineAntimetabolites, AntineoplasticHeat-Shock Response

Stichwörter der Autor:innen

HSF1HSP27HSP90aminoguanidinegemcitabineglycolysismetforminmethylglyoxaloncometabolitetherapy resistance

Substanzen

GemcitabinePyruvaldehydeDeoxycytidineAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Metastasis Research Laboratory, GIGA-Cancer, GIGA Institute, University of Liège, 4020 Liège, Belgium.
  • Department of Human Genetics, Liège University Hospital, 4020 Liège, Belgium.
  • Department of Pathology, Hôpital Universitaire de Bruxelles Bordet Erasme l Hospital, Université Libre de Bruxelles, 1000 Brussels, Belgium.
  • Laboratory of Experimental Gastroenterology, Medical Faculty, Université Libre de Bruxelles, 1000 Brussels, Belgium.
  • Department of Gastroenterology, Hepatology and Digestive Oncology, Hôpital Universitaire de Bruxelles Bordet Erasme Hospital, Université Libre de Bruxelles, 1000 Brussels, Belgium.

ORCID-Profile: Raphaël Peiffer, Benjamin Koopmansch, Frédéric Lambert, Olivier Peulen, Akeila Bellahcène

Förderung

  • collaborative FNRS grant awarded to A.B. and J.-L.V.L.
  • University of Liège
  • “Fondation Léon Fredericq”

Zitieren

APA

Crake, R., Gasmi, I., Dehaye, J., Lardinois, F., Peiffer, R., Maloujahmoum, N., Agirman, F., Koopmansch, B., D'Haene, N., Azurmendi Senar, O., Arsenijevic, T., Lambert, F., Peulen, O., Van Laethem, J. L., & Bellahcène, A. (2023). Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response. Cells, 12(10), 1414. https://doi.org/10.3390/cells12101414

Vancouver

Crake R, Gasmi I, Dehaye J, Lardinois F, Peiffer R, Maloujahmoum N, et al. Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response. Cells. 2023;12(10):1414. doi:10.3390/cells12101414

BibTeX
@article{Crake2023,
  author = {Crake, Rebekah and Gasmi, Imène and Dehaye, Jordan and Lardinois, Fanny and Peiffer, Raphaël and Maloujahmoum, Naïma and Agirman, Ferman and Koopmansch, Benjamin and D'Haene, Nicky and Azurmendi Senar, Oier and Arsenijevic, Tatjana and Lambert, Frédéric and Peulen, Olivier and Van Laethem, Jean-Luc and Bellahcène, Akeila},
  title = {Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {10},
  pages = {1414},
  doi = {10.3390/cells12101414}
}
Kostenlos starten →